Q3 Earnings Estimate for Evommune Issued By Leerink Partnrs

Evommune, Inc. (NYSE:EVMN) – Research analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for Evommune in a research report issued to clients and investors on Monday, December 1st. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($1.00) for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. Leerink Partnrs also issued estimates for Evommune’s Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($3.00) EPS, Q1 2026 earnings at ($0.66) EPS, Q2 2026 earnings at ($0.63) EPS, Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($2.53) EPS, FY2027 earnings at ($2.81) EPS, FY2028 earnings at ($3.78) EPS and FY2029 earnings at ($4.92) EPS.

Other analysts also recently issued reports about the stock. Morgan Stanley initiated coverage on shares of Evommune in a research report on Monday. They set an “overweight” rating and a $36.00 price objective on the stock. Wall Street Zen raised Evommune to a “hold” rating in a report on Thursday, November 20th. Evercore ISI initiated coverage on Evommune in a research note on Monday. They issued an “outperform” rating and a $40.00 price objective for the company. Leerink Partners assumed coverage on Evommune in a research report on Monday. They set an “outperform” rating and a $42.00 target price for the company. Finally, Cantor Fitzgerald assumed coverage on Evommune in a report on Monday. They issued an “overweight” rating on the stock. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $39.33.

Evommune Stock Performance

Shares of NYSE:EVMN opened at $21.97 on Wednesday. Evommune has a 1-year low of $16.70 and a 1-year high of $24.03.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.